The Belgium Financial Services and Markets Authority has amended its Biotech Opinion to reflect the Listing Act provisions that changed the Market Abuse Regulation in June 2026 and Delegated Regulation (EU) 2026/789, which provides a nonexhaustive list of final events or circumstances in protracted processes.
Belgium Financial Services and Markets Authority updates Biotech Opinion for revised inside information rules on protracted processes
The Belgium Financial Services and Markets Authority has updated its Biotech Opinion to reflect revised Market Abuse Regulation requirements and the EU list of final events or circumstances in protracted processes.